The pharmaceutical industry has spent much of the past decade performing a kind of collective memory erasure about small molecules. […]

A reference-grade guide for generic drug IP teams, litigation counsel, portfolio managers, business development executives, and institutional investors who need

How integrating patent, clinical, and scientific data into a single intelligence engine is replacing guesswork in life sciences strategy—and what

How patent intelligence, regulatory mastery, and manufacturing technology are separating the winners from the commoditized in a $700 billion market

A technical deep-dive for IP counsel, 503B portfolio managers, brand lifecycle teams, and institutional investors tracking the $10.93B compounding market.

1. Why Method-of-Use Patents Now Control More Revenue Than Compound Patents A structural shift has occurred in pharmaceutical patent litigation

I. Executive Summary The U.S. pharmaceutical patent system is not a passive legal framework. It is an engineered adversarial machine,

A comprehensive technical guide to building event-driven pharmaceutical cost forecasts using patent expiration data, FDA exclusivity calendars, Paragraph IV litigation

The global generic drug market will cross $700 billion by the early 2030s. Individual companies inside it are getting crushed.